Figure 2.
SV.IL12 in Combination with Anti-OX40 Antibody Cures Established Tumors In Vivo
(A) Experimental protocol for the prostate and colon cancer model used in (B)–(E). FVB/NJ or BALB/c mice were given an i.p. injection of SV.IL12 and/or anti-OX40 at various times after injection of 105 MyC-CaP.Fluc or 7 × 104 CT26.Fluc cells on day 0, respectively. (B) CT26.Fluc tumor growth curves are shown as fold changes relative to the luminescence on day 0 of the same mouse. Each line represents an individual mouse. Left graphs: control (n = 14) (top) and SV.IL12 (n = 20) (bottom). Right graphs: anti-OX40 (n = 10) (top) and SV.IL12+anti-OX40 (n = 11) (bottom). (C) Representative bioluminescence images of control and treated CT26.Fluc-bearing mice. (D and E) Survival plots of control and treated mice bearing peritoneally disseminated CT26.Fluc (D) or MyC-CaP.Fluc (E) tumors. Statistical significances between SV.IL12+anti-OX40 and anti-OX40 or SV.IL12 were determined with the Mantel-Cox test. Results are representatives of at least two independent experiments. αOX40/aOX40, anti-OX40.